BCAB — BioAtla, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1826892 ·
Last close
$1.48
Market Cap
$2.47M
52W High
$71.50
52W Low
$1.07
ADV30
91,580
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 6,500,000 | — | 227,000 | 452,000 | 9,506,000 | 1,544,000 | 45,742,000 |
| Mar 2026 | 0 | — | -9,308,000 | -6,344,000 | 8,566,000 | 1,961,000 | 45,875,000 |
| Dec 2025 | 2,000,000 | — | -9,255,000 | -9,784,000 | 13,828,000 | 7,118,000 | 50,017,000 |
| Sep 2025 | 0 | — | -13,789,000 | -15,778,000 | 15,908,000 | 8,320,000 | 47,145,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-37,183,000
Investing CF
$0
Financing CF
$6,781,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-41.72
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-551,990,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-50,999,000
Pretax Income TTM
$-50,617,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,500,000
EBITDA
$-30,830,000
Free Cash Flow
$-11,860,625
Enterprise Value
$6,818,150
Total Cash
$1,544,000
Total Debt
$5,863,000
Shares Out
1,666,100
Trailing EPS
$-25.07
Book Value
$-21.79
ROE
—
ROA
-105.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,000,000 | -59,305,000 | -59,607,000 | 13,828,000 | 50,017,000 | -36,189,000 | -48,204,000 |
| Dec 2024 | 11,000,000 | -73,943,000 | -69,776,000 | 52,422,000 | 38,157,000 | 14,265,000 | -71,936,000 |
| Dec 2023 | 0 | -129,687,000 | -123,462,000 | 119,658,000 | 48,986,000 | 70,672,000 | -104,015,000 |
| Dec 2022 | 0 | -108,140,000 | -106,482,000 | 225,736,000 | 45,397,000 | 180,339,000 | -90,420,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABPO | Abpro Holdings, Inc. | $2.42M | $0.41 | — |
| CLDI | Calidi Biotherapeutics, Inc. | $2.92M | $1.13 | — |
| VIVS | VivoSim Labs, INC. | $2.95M | $0.22 | — |
| CRIS | CURIS INC | $2.01M | $0.83 | — |
| SLXN | Silexion Therapeutics Corp | $1.45M | $0.26 | — |
News headlines (Yahoo Finance, 1h cache)
BioAtla Announces Share Consolidation
2026-03-31 20:06 · Yahoo
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2026-03-31 20:05 · Yahoo
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
2026-05-18 10:45 · Yahoo
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
2026-03-02 12:30 · Yahoo
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma
2025-12-31 12:00 · Yahoo
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
2025-11-21 05:25 · Yahoo
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...
2025-11-14 05:04 · Yahoo
BioAtla (BCAB) Q3 2025 Earnings Call Transcript
2025-11-13 22:07 · Yahoo
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
2025-11-13 21:05 · Yahoo
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
2025-11-07 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.